148 related articles for article (PubMed ID: 2839394)
21. [Studies on CA 125, CA 19-9, TPA and IAP as tumor markers in patients with ovarian cancer].
Negishi Y; Furuno K; Sano Y; Hirata T; Utsunomiya A; Nakajima H; Okabe K; Shimizu K; Akiya K; Fujiwara Y
Gan No Rinsho; 1985 May; 31(6 Suppl):655-63. PubMed ID: 2993692
[TBL] [Abstract][Full Text] [Related]
22. CA19-9 as a marker for ovarian cancer: alone and in comparison with CA125.
Canney PA; Wilkinson PM; James RD; Moore M
Br J Cancer; 1985 Jul; 52(1):131-3. PubMed ID: 2410004
[No Abstract] [Full Text] [Related]
23. [Clinical significance of new tumor marker CA 125 in gynecological cancer--particularly usefulness in diagnosis of ovarian cancer].
Kimura E; Murae M; Koga R; Odawara Y; Nakabayashi Y; Yokoyama K; Nakata H; Totake T; Ochiai K; Yasuda M
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Nov; 36(11):2121-8. PubMed ID: 6595320
[TBL] [Abstract][Full Text] [Related]
24. Clinical use of CA 125 and its combination assay with other tumor marker in patients with ovarian carcinoma.
Negishi Y; Furukawa T; Oka T; Sakamoto M; Hirata T; Okabe K; Matayoshi K; Akiya K; Soma H
Gynecol Obstet Invest; 1987; 23(3):200-7. PubMed ID: 3474196
[TBL] [Abstract][Full Text] [Related]
25. Preoperative determination of several serum tumor markers in patients with primary epithelial ovarian carcinoma.
Kudoh K; Kikuchi Y; Kita T; Tode T; Takano M; Hirata J; Mano Y; Yamamoto K; Nagata I
Gynecol Obstet Invest; 1999; 47(1):52-7. PubMed ID: 9852392
[TBL] [Abstract][Full Text] [Related]
26. Evaluation of CA125 as a circulating tumor marker for ovarian cancer.
Kuzuya K; Nozaki M; Chihara T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):949-57. PubMed ID: 3461071
[TBL] [Abstract][Full Text] [Related]
27. A radioimmunoassay using a monoclonal antibody to monitor the course of epithelial ovarian cancer.
Bast RC; Klug TL; St John E; Jenison E; Niloff JM; Lazarus H; Berkowitz RS; Leavitt T; Griffiths CT; Parker L; Zurawski VR; Knapp RC
N Engl J Med; 1983 Oct; 309(15):883-7. PubMed ID: 6310399
[TBL] [Abstract][Full Text] [Related]
28. [Clinical usefulness of the combination assay of CA 125, SLX, and CA 72-4 in patients with ovarian cancer].
Kobayashi H; Kawashima Y
Nihon Sanka Fujinka Gakkai Zasshi; 1989 Nov; 41(11):1731-5. PubMed ID: 2574209
[TBL] [Abstract][Full Text] [Related]
29. Significance of multiparameter flow cytometric analysis of ovarian cancer.
Fowler WC; Maddock MB; Moore DH; Haskill S
Am J Obstet Gynecol; 1988 Apr; 158(4):838-45. PubMed ID: 3163230
[TBL] [Abstract][Full Text] [Related]
30. Immunohistochemical and immunoelectron microscopic study of an amylase-producing, CA19-9 positive ovarian mucinous cystadenocarcinoma.
Teshima H; Kitamura H; Mizoguchi Y; Hino S; Mizutani K; Mori H; Kigawa T
Gynecol Oncol; 1988 Jul; 30(3):372-80. PubMed ID: 2455679
[TBL] [Abstract][Full Text] [Related]
31. A new CA125-like antigen (CA602) recognized by two monoclonal antibodies against a newly established ovarian clear cell carcinoma cell line (RMG-II).
Nozawa S; Yajima M; Sasaki H; Tsukazaki K; Aoki D; Sakayori M; Udagawa Y; Kobayashi T; Sato I; Furusako S
Jpn J Cancer Res; 1991 Jul; 82(7):854-61. PubMed ID: 1715339
[TBL] [Abstract][Full Text] [Related]
32. [Analysis of serum CA125, CEA, AFP, LDH levels and LDH isoenzymes in patients with ovarian tumors--correlation between tumor markers and histological types of ovarian tumors].
Konishi I; Fujii S; Okamura H; Sakahara H; Endo K; Torizuka K; Suzuki A; Mori T
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Jun; 38(6):827-36. PubMed ID: 2426374
[TBL] [Abstract][Full Text] [Related]
33. Circulating DF3 and CA125 antigen levels in serum from patients with epithelial ovarian carcinoma.
Sekine H; Hayes DF; Ohno T; Keefe KA; Schaetzl E; Bast RC; Knapp R; Kufe DW
J Clin Oncol; 1985 Oct; 3(10):1355-63. PubMed ID: 2413181
[TBL] [Abstract][Full Text] [Related]
34. Tumor associated antigen in ovarian carcinoma.
Negishi Y; Mutai Y; Akiya K; Fujiwara Y; Singh G
Nihon Sanka Fujinka Gakkai Zasshi; 1984 Jan; 36(1):126-32. PubMed ID: 6199439
[TBL] [Abstract][Full Text] [Related]
35. [Serum CA125 in malignant ovarian tumor--periodical monitoring and correlation with other tumor markers].
Kawai M; Yamashita H; Hayashi T; Kamiya N; Kakihara M; Arii Y
Nihon Sanka Fujinka Gakkai Zasshi; 1986 Mar; 38(3):402-10. PubMed ID: 3457877
[TBL] [Abstract][Full Text] [Related]
36. CAM26, CAM29 and mucin-like carcinoma associated antigen in epithelial ovarian cancer.
Ferdeghini M; Gadducci A; dell'Hoste M; Prontera C; Ceccarini T; Rispoli G; Bianchi R; Fioretti P
Eur J Gynaecol Oncol; 1990; 11(5):395-401. PubMed ID: 1965803
[TBL] [Abstract][Full Text] [Related]
37. [Diagnostic usefulness of stepwise discriminant analysis employing the values of CA125, TPA, IAP, CEA and ferritin in sera measured simultaneously for gynecological malignant neoplasms].
Yabushita H; Masuda T; Hattori A; Noguchi M; Ito Y; Nakanishi M; Ishihara M
Nihon Sanka Fujinka Gakkai Zasshi; 1985 Sep; 37(9):1883-92. PubMed ID: 2997349
[TBL] [Abstract][Full Text] [Related]
38. Serum levels of CA-125 in patients with endometriosis: a preliminary report.
Giudice LC; Jacobs A; Pineda J; Bell CE; Lippmann L
Fertil Steril; 1986 Jun; 45(6):876-8. PubMed ID: 3458595
[TBL] [Abstract][Full Text] [Related]
39. [Clinical value of a new serum tumor marker CA602 in ovarian cancers].
Suzuki M; Sekiguchi I; Ohwada M; Aida I; Tamada T
Nihon Gan Chiryo Gakkai Shi; 1990 Jul; 25(7):1454-60. PubMed ID: 2170549
[TBL] [Abstract][Full Text] [Related]
40. Detection of human ovarian tumor-associated antigens by sandwich enzyme immunoassay.
Rao GS; Hanjani P
Obstet Gynecol; 1988 Mar; 71(3 Pt 1):423-8. PubMed ID: 3279355
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
